EpicentRx’s Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment
Dec 4, 2024
How alright are we about AdAPT-001 Fast Track Designation? Click on the image to play and find out.
